Abstract:
Disclosed are methods of treating a subject having high-risk multiple myeloma, methods of achieving negative minimal residual disease status in a subject having multiple myeloma, and methods of predicting a likelihood of, or decreasing a risk of, relapse and/or disease progression in a subject having multiple myeloma.
Abstract:
The present invention relates to methods of immunomodulation and treating patients having solid tumors with antibodies that specifically bind CD38.
Abstract:
The present invention relates to methods of immunomodulation and treating patients having solid tumors with antibodies that specifically bind CD38.
Abstract:
The present invention relates to methods of immunomodulation and treating patients having solid tumors with antibodies that specifically bind CD38.
Abstract:
Disclosed are methods of treating a subject having high-risk multiple myeloma, methods of achieving negative minimal residual disease status in a subject having multiple myeloma, and methods of predicting a likelihood of, or decreasing a risk of, relapse and/or disease progression in a subject having multiple myeloma.
Abstract:
Disclosed are methods of treating a subject having high-risk multiple myeloma, methods of achieving negative minimal residual disease status in a subject having multiple myeloma, and methods of predicting a likelihood of, or decreasing a risk of, relapse and/or disease progression in a subject having multiple myeloma.
Abstract:
The present invention relates to methods of immunomodulation and treating patients having solid tumors with antibodies that specifically bind CD38.
Abstract:
The present invention relates to methods of immunomodulation and treating patients having solid tumors with antibodies that specifically bind CD38.
Abstract:
The present invention relates to methods of immunomodulation and treating patients having solid tumors with antibodies that specifically bind CD38.